Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group
Online Formulary

2. Cardiovascular system - guidance

To access BNF Formulary section click on the link under BNF Section/s

To access the Guidance Document click on the highlighted text under the Title column

Use documents past their review date with Caution

 

BNF Section/s Title Issuing Body  Version Date of Issue / Review Update Due
2.3.2.3 Andexanet alfa - Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban  - TA697  NICE    May 2021  -

2.3.2, 2.3.2.2,  2.3.2.5

Apixaban,  Edoxaban, Rivaroxaban and Dabigatran

Anticoagulant prescribing -

Click here for K&M Anticoagulant position statement and risk mitigation principles.
            --------------
NHSE updated the Commissioning recommendations for national procurement for direct-acting oral anticoagulant(s) (DOACs) on the 6th of September 2024. This document will be reviewed ASAP, via the normal ICB governance process, to reflect the current NHSE recommendations. 

 Kent and Medway  
ICB		   Feb 2025 Feb 2026
2.3.2.2 Apixaban - Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults TA245  NICE   Jan 2012  - 
2.3.2  2.3.2.2
 Atrial fibrillation - Atrial fibrillation: diagnosis and management NG196 NICE    Jun 2021  - 
2.6 Bempedoic Acid/Ezetimibe - BEMPEDOIC ACID WITH EZETIMIBE (Nilemdo and Nustendi) for treating primary hypercholesterolemia or mixed dyslipidaemia. Implementation guidance for Nice TA694  Kent and Medway  CCG   Sep 2021 Sep 2022 !
2.3.2.5 Dabigatran etexilate -Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults - TA157  NICE   Sept 2008  - 
2.3.2.5 Dabigatran etexilate - Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation  TA249  NICE   Jul 2021  - 
2.5.3 Dapagliflozin & Empagliflozin - K&M Implementation of NICE TA’s – SGLT2 inhibitors (Dapagliflozin & Empagliflozin) in the treatment of chronic heart failure Kent and Medway  ICB   Aug 2023 Aug 2025
2.5.3 Dapagliflozin - Dapagliflozin for treating chronic heart failure with reduced ejection fraction TA679  NICE   Feb 2021  -
2.5.3 Dapagliflozin - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction TA902 NICE   Jun 2023  -
2.5.3
6.3.1.4		 Dapagliflozin - Dapagliflozin for treating chronic kidney disease TA775 NICE   Mar 2022  - 

2.3.2.2

 DOAC -  Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment MHRA
Drug Safety Update		   May 2023  -

2.3.2.2

DOAC Monitoring - DOAC Monitoring Recommendations for Non-Valvular Atrial Fibrillation (NVAF) in Primary Care
This document is under review. In the meantime please refer to DOACs (Direct Oral Anticoagulants) monitoring – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice and Anticoagulation - oral | Health topics A to Z | CKS | NICE for advice on DOAC monitoring, also noting manufacturer’s SmPC Home - electronic medicines compendium (emc), and to the MHRA on calculating renal function using creatinine clearance for dosing DOACs (MHRA Click here)

 Kent and Medway  CCG   Dec 2021 Dec 2023 !
2.5.3 Empagliflozin - Empagliflozin for treating chronic heart failure with reduced ejection fraction TA773 NICE   Mar 2022  - 

2.5.3

 Empagliflozin - Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction TA929
 NICE   Nov 2023 -

2.5.3

 Empagliflozin - Empagliflozin for treating chronic kidney disease TA942 NICE   Dec 2023 -

2.3.1

  Epoprostenol   High-Cost Drugs      

2.5.1  6.3.1.4

 Finerenone - Finerenone for treating chronic kidney disease in type 2 diabetes TA877
 NICE   Mar 2023 -
2.6 Icosapent  -  Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides TA805 NICE   Jul 2022 -
2.6 Inclisiran - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia TA733​ NICE   Oct 2021 -
2.6 Inclisiran - Kent & Medway ICB Position Statement
Prescribing Inclisiran (Leqvio®) for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia in Kent and Medway		 Kent and Medway ICB   Jul 2023 Jul 2025
2.6 Lipid Management - Summary of National Guidance for Lipid Management for
Primary and Secondary Prevention of CVD		 NICE /National Guidance   Mar 2024 -
2.4.1.4 Metolazone - MHRA Xaqua (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations MHRA
Drug Safety Update		   Jan 2023  - 
2.4.1.4 Metolazone -  Metolazone (Xaqua) prescribing position statement   Kent and Medway  ICB  1.1 Jun 2024 Jun 2026
2.4.1.4 Metolazone - Metolazone (Xaqua) Patient Information Kent and Medway  ICB     Jun 2024 Jun 2026
2.3.2.2 Rivaroxaban - Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults - TA170 NICE   Apr 2009  - 
2.3.2.2 Rivaroxaban - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (PE)  TA261 NICE   Jul 2012  -
2.5.2 Sacubitril + Valsartan - Sacubitril + Valsartan prescribing Guidance   MCH/Medway & Swale CCG   Sep 2016  -

2.5.3 6.3.1.4

 SGLT2 - SGLT2 inhibitors for Chronic Kidney Disease (CKD) in Adults Kent and Medway  ICB   Jun 2024  Jun 2026
2.3.2.6 Warfarin - Guidance for switching from Warfarin to DOACs -  Kent and Medway  CCG 1 Jun 2020  -
           

 

 

 

 

 

 

 

 

 

  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •